Search results for "enzyme inhibitors"

showing 10 items of 559 documents

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After A…

2017

Abstract: The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originall…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier Estimate030204 cardiovascular system & hematologyVentricular Function Leftchemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineRetrospective StudieRisk FactorsClinical endpointOdds Ratiozofenopril030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as Topicleft ventricular dysfunctionMortality ratePharmacology; Cardiology and Cardiovascular MedicineMiddle AgedZofenoprilHospitalizationTreatment OutcomeCardiologyOriginal ArticleDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineHumanmedicine.drugRamiprilmedicine.medical_specialtyLogistic ModelTime FactorSystoleacute myocardial infarctionramiprilDisease-Free SurvivalDrug Administration ScheduleFollow-Up Studie03 medical and health sciencesStatistical significanceInternal medicineEarly Medical InterventionmedicineHumansIntensive care medicineAgedRetrospective StudiesPharmacologyChi-Square DistributionAspirinbusiness.industryRisk FactorAngiotensin-Converting Enzyme InhibitorOdds ratioRecovery of Functionmedicine.diseaseConfidence intervalLogistic ModelschemistryClinical Trials Phase III as Topicbusinessacetyl salicylic acidFollow-Up StudiesJournal of Cardiovascular Pharmacology
researchProduct

Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acut…

2012

Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with left ventricular dysfunction (LVD), but their efficacy may be negatively affected by concomitant administration of acetylsalicylic acid (ASA), with some difference among the different compounds. Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs. Methods: This phase IIIb, randomized, double-blind, parallel-group, multicenter, European study compared the safety and efficacy of zofenopril (60 mg/day) and ramipril (10 mg/d…

MaleCaptoprilTime FactorsMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateVentricular Function Leftlaw.inventionchemistry.chemical_compoundVentricular Dysfunction LeftRandomized controlled trialRamiprillawRisk FactorsOdds RatioMyocardial infarctionProspective Studieseducation.field_of_studyEjection fractionGeneral MedicineMiddle AgedZofenoprilEuropeHospitalizationTreatment OutcomeCardiologyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugRamiprilmedicine.medical_specialtySystolePopulationClinical InvestigationsRisk AssessmentDouble-Blind MethodInternal medicinemedicineHumanseducationAgedHeart FailureChi-Square DistributionAspirinbusiness.industryStroke Volumeacetylsalicylic acidmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryLogistic ModelschemistryAngiotensin-converting enzyme inhibitorHeart failureMyocardial infarction complicationsZofenopril ramipril myocardial infarctionbusinessPlatelet Aggregation Inhibitors
researchProduct

Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity

2003

Abstract Background/Aims : The role of oxidative stress in diclofenac hepatotoxicity is still not clear. This study examined whether the drug induced heme oxygenase-1 (HO-1), a stress protein. Methods : HO-1 mRNA and HO activity were measured in mouse liver and in rat hepatocytes after treatment with diclofenac parallel to release of serum alanine aminotransferase (ALT) and sorbitol dehydrogenase (SDH) as a marker of hepatic damage. Results : HO-1 was transcriptionally and dose-dependently induced by diclofenac in mouse liver and rat hepatocytes. HO-1 mRNA, ALT and SDH peaked at the same time. Mechanistic studies revealed that the drug synergized with buthionine sulfoximine (BSO) in lowerin…

MaleCarcinoma HepatocellularDiclofenacCytochromeMice Inbred StrainsOxidative phosphorylationPharmacologymedicine.disease_causeMicechemistry.chemical_compoundCytochrome P-450 Enzyme SystemCell Line TumormedicineAnimalsCytochrome P-450 Enzyme InhibitorsHumansButhionine sulfoximineEnzyme InhibitorsButhionine SulfoximineDose-Response Relationship DrugHepatologybiologyLiver NeoplasmsMembrane ProteinsCytochrome P450GlutathioneAcetylcysteineRatsHeme oxygenaseOxidative Stressstomatognathic diseasesmedicine.anatomical_structureLiverchemistryBiochemistryEnzyme InductionHepatocyteHeme Oxygenase (Decyclizing)Hepatocytesbiology.proteinFemaleHeme Oxygenase-1Oxidative stressJournal of Hepatology
researchProduct

Statins and other drugs: Facing COVID-19 as a vascular disease

2020

Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors ("statins") have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19-infected older adults residing in nursing homes.We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ARB and/or statin use with clinical outcome of COVID-19. The …

MaleCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAngiotensin-Converting Enzyme InhibitorsRisk AssessmentSeverity of Illness IndexCohort StudiesBetacoronavirusAngiotensin Receptor AntagonistsBelgiumStatins Drugs COVID-19 Vascular DiseaseCause of DeathVascular DiseasePandemicOdds RatioHomes for the AgedHumansMedicineVascular DiseasesLetter to the EditorGeriatric AssessmentPandemicsAgedRetrospective StudiesAged 80 and overPharmacologybiologySARS-CoV-2business.industryVascular diseaseStatinsDrugsCOVID-19medicine.diseasebiology.organism_classificationVirologyNursing HomesSurvival RatePneumoniaLogistic ModelsTreatment OutcomeFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsCoronavirus InfectionsbusinessNursing homesCoronavirus InfectionsBetacoronavirusPharmacological Research
researchProduct

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

2020

Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66±0.4 years) were r…

MaleCross-sectional studyAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyRenin-Angiotensin System0302 clinical medicine80 and overMedicineodds ratioodds ratio.030212 general & internal medicineViralYoung adultSocieties MedicalAged 80 and overCOVID-19; hypertension; Italy; multimorbidity; odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalMortality rateAge FactorsMiddle AgedPrognosisSurvival RateItalyCOVID-19; hypertension; Italy; multimorbidity; odds ratioFemaleCoronavirus InfectionsAdultmedicine.medical_specialtyhypertensionAdolescentmultimorbidityPneumonia ViralCOVID-19; Italy; hypertension; multimorbidity; odds ratio03 medical and health sciencesAngiotensin Receptor AntagonistsYoung AdultBetacoronavirusAge DistributionInternal medicineDiabetes mellitusMedicalInternal MedicineHumansSurvival ratePandemicsAgedbusiness.industrySARS-CoV-2COVID-19Odds ratioPneumoniamedicine.diseaseCross-Sectional StudiesHeart failureCOVID-19; Hypertension; Italy; Multimorbidity; Odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; SARS-CoV-2; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalbusinessSocietiesKidney disease
researchProduct

Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor…

1996

Oxidation of tienilic acid by human cytochromes P-450 (CYP) 2C9, 2C18, 2C8 and 2C19 was studied using recombinant enzymes expressed in yeast. CYP 2C9 was the best catalyst for 5-hydroxylation of tienilic acid (K(m) = 5 +/- 1 microM, kcat = 1.7 +/- 0.2 min-1), 30-fold more potent in terms of kcat/K(m) than CYP 2C18 (K(m) = 150 +/- 15 microM, kcat = 1.8 +/- 0.2 min-1) and 300-fold more potent than CYP 2C8 (K(m) = 145 +/- 15 microM, kcat = 0.2 +/- 0.1 min-1). CYP 2C19 was unable to catalyze this hydroxylation under our experimental conditions. During this study, a marked effect of the ionic strength on the activities (hydroxylations of tienilic acid and tolbutamide) of these cytochromes P-450 …

MaleCytochromeTolbutamideTicrynafenSaccharomyces cerevisiaeurologic and male genital diseasesHydroxylationBiochemistryMixed Function OxygenasesHydroxylationchemistry.chemical_compoundCytochrome P-450 Enzyme SystemMicrosomesmedicineCytochrome P-450 Enzyme InhibitorsHumansheterocyclic compoundsEnzyme InhibitorsCytochrome P-450 Enzyme Inhibitorschemistry.chemical_classificationbiologyChemistryorganic chemicalsMembrane ProteinsGlutathionerespiratory systemRecombinant ProteinsIsoenzymesenzymes and coenzymes (carbohydrates)EnzymeBiochemistrySteroid 16-alpha-HydroxylaseTienilic acidSuicide inhibitionbiology.proteinMicrosomeMicrosomes LiverAryl Hydrocarbon HydroxylasesOxidation-Reductionmedicine.drugEuropean journal of biochemistry
researchProduct

Ethoxyquin as an inducer and inhibitor of phenobarbital-type cytochrome P-450 in rat liver microsomes.

1977

Abstract The effect of ethoxyquin in vivo and in vitro on drug metabolism in rat liver microsomes was studied. In feeding experiments, a threshold dose of induction was found at 0.05% ethoxyquin for 14 days. At 0.5% ethoxyquin, relative liver weight, cytochrome P-450 content, cytochrome b5 content, ethylmorphine demethylation, and ethoxycoumarin deethylation were increased by a factor of 1.5 to 2. Aryl hydrocarbon hydroxylase activity was, however, not induced but even decreased by 0.5% ethoxyquin in food. Induction of epoxide hydratase was marked, amounting to 400% of control after 0.5% ethoxyquin. The induced enzyme was similar to the phenobarbital-inducible cytochrome P-450 in its CO spe…

MaleCytochromeToxicologyMixed Function OxygenasesHydroxylationchemistry.chemical_compoundEthoxyquinCytochrome P-450 Enzyme SystemCytochrome b5AnimalsCytochrome P-450 Enzyme InhibitorsDemethylationPharmacologyEthoxyquinbiologyChemistryOrgan SizeMonooxygenaseRatsBiochemistryEnzyme InductionPhenobarbitalMicrosomebiology.proteinMicrosomes LiverQuinolinesElectrophoresis Polyacrylamide GelDrug metabolismToxicology and applied pharmacology
researchProduct

Influence of template inactivators on the binding of DNA polymerase to DNA.

1974

The agents daunomycin, ethidium bromide, distamycin A and cytochrome c inhibit DNA dependent DNA polymerase I (E. coli) reaction competitively to DNA. The influence of these template inactivators on the binding of DNA polymerase to native as well as denatured DNA has been determined by affinity chromatography. Cytochrome c blocks the binding of the enzyme to double-stranded and to single-stranded DNA Sepharose. In contrast to these results daunomycin, ethidium bromide or distamycin A reduce the binding affinity only with denatured DNA Sepharose as matrix. These data are discussed with respect to the modification by template inactivators of the affinity of DNA to the different binding sites …

MaleDNA polymeraseDNA polymerase IICytochrome c GroupIn Vitro Techniqueschemistry.chemical_compoundNucleic acid thermodynamicsEthidiumGeneticsAnimalsEnzyme InhibitorsPolymeraseDNA clampBinding SitesbiologyDaunorubicinDistamycinsDNADNA Polymerase IMolecular biologyKineticschemistryBiochemistrybiology.proteinPrimer (molecular biology)DNA polymerase IDNANucleic acids research
researchProduct

Negative regulation of diacylglycerol kinase θ mediates adenosine-dependent hepatocyte preconditioning

2010

In liver ischemic preconditioning (IP), stimulation of adenosine A2a receptors (A2aR) prevents ischemia/reperfusion injury by promoting diacylglycerol-mediated activation of protein kinase C (PKC). By concerting diacylglycerol to phosphatidic acid, diacylglycerol kinases (DGKs) act as terminator of diacylglycerol signalling. This study investigates the role of DGK in the development of hepatocyte IP. DGK activity and cell viability were evaluated in isolated rat hepatocytes preconditioned by 10 min hypoxia followed by 10 min re-oxygenation or by the treatment with the A2aR agonist, CGS21680, and subsequently exposed to prolonged hypoxia. We observed that after IP or A2aR activation, a decre…

MaleDiacylglycerol Kinasemedicine.medical_specialtyAdenosineReceptor Adenosine A2Ap38 mitogen-activated protein kinasesBiologyQuinazolinonechemistry.chemical_compoundPiperidinecytoprotectionPiperidinesDownregulation and upregulationDiacylglycerol kinase thetaInternal medicinemedicineEnzyme Inhibitorhepatocytes adenosine RhoA hypoxia cytoprotectionAnimalsHepatocyteEnzyme InhibitorsRats WistarMolecular BiologyCells CulturedProtein kinase CQuinazolinonesDiacylglycerol kinaseCell DeathAnimalhypoxiaKinaseReceptors Purinergic P1RhoACell BiologyPhosphatidic acidAdenosineCell HypoxiaRatsCell biologyEndocrinologychemistryHepatocytesRatrhoA GTP-Binding Proteinmedicine.drugCell Death & Differentiation
researchProduct